No Data
No Data
StemRIM to Seek Shareholders' Approval on Capital Stock Reduction
Pharmaceutical firm StemRIM (TYO:4599) will hold an extraordinary general meeting of shareholders on July 24 to vote on the company's proposed capital stock reduction, according to a Wednesday filing.
StemRIM Allocates 300 Stock Options to R&D Partner
StemRIM (TYO:4599) allocated 300 stock option units, or 30,000 common shares, to an unnamed partner in a research and development collaboration, according to a Thursday bourse filing, The exercise pri
StemRIM to Issue Stock Acquisition Rights
StemRIM (TYO:4599) is undertaking a stock option issuance to its external collaborator without costs, to enhance research and development for its Regeneration-Inducing Medicine, according to its filin
StemRIM Issues Over 300 Million Yen of Shares as Restricted Stock Compensation
StemRIM (TYO:4599) issued 433,000 shares for 307.4 million yen, or 710 yen apiece, as restricted stock compensation, according to a Wednesday bourse filing. The biotech company issued 393,000 shares t
StemRIM Issues 433,000 Shares as Restricted Stock Compensation
StemRIM (TYO:4599) is issuing 433,000 shares for 710 yen per share or 307.43 million yen as restricted stock compensation, according to its filing on Thursday. The biotechnology company has allotted 3
StemRIM, Shiseido, Osaka University Extend Skin Aging Research Collaboration
StemRIM (TYO:4599), Shiseido (TYO:4911) and Osaka University have extended their research collaboration, building on data gathered from their research on the aging mechanisms of skin stem cells, a Thu
No Data